# DNA X, Inc.: overview SONM · Nasdaq · CIK 1178697 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/sonm.md) · [Financials](/companies/sonm/financials.md) · [Filings](/companies/sonm/filings.md) · [Insiders](/companies/sonm/insiders.md) Latest reported revenue: [$16.2m](/filings/0001493152-25-020310.md) for Q3 FY2025, three months to 2025-09-30, from the 10-Q filed Oct 31, 2025 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-25-020310). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [15.0](/filings/0001493152-25-020310.md) | [15.3 d](/filings/0001641172-25-001720.md) | [16.7](/filings/0001641172-25-009749.md) | [11.2](/filings/0001641172-25-022821.md) | [16.2](/filings/0001493152-25-020310.md) | not reported | not reported | not reported | | Gross margin | % | [28.2%](/filings/0001493152-25-020310.md) | [(1.2%) d](/filings/0001641172-25-001720.md) | [50.0%](/filings/0001641172-25-009749.md) | [7.6%](/filings/0001641172-25-022821.md) | [11.2%](/filings/0001493152-25-020310.md) | not reported | not reported | not reported | | Operating margin | % | [(15.8%)](/filings/0001493152-25-020310.md) | [55.3% d](/filings/0001493152-26-016659.md) | [(5.2%)](/filings/0001493152-26-024644.md) | [(13.1%)](/filings/0001493152-26-039226.md) | [(24.5%)](/filings/0001493152-25-020310.md) | not reported | not reported | not reported | | Net margin | % | [(16.7%)](/filings/0001493152-25-020310.md) | [(141.6%) d](/filings/0001493152-26-016659.md) | [2.7%](/filings/0001493152-26-024644.md) | [(66.8%)](/filings/0001493152-26-039226.md) | [(29.3%)](/filings/0001493152-25-020310.md) | not reported | not reported | not reported | | Diluted EPS | $ per share | [(9.32)](/filings/0001493152-25-020310.md) | not reported | [1.41](/filings/0001493152-26-024644.md) | [(14.15)](/filings/0001493152-26-039226.md) | [(4.83)](/filings/0001493152-25-020310.md) | not reported | [5.01](/filings/0001493152-26-024644.md) | [(0.92)](/filings/0001493152-26-039226.md) | | Free cash flow | $m | [(0.6) d](/filings/0001493152-25-020310.md) | [(4.5) d](/filings/0001493152-26-016659.md) | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [54.6](/filings/0001493152-23-008199.md) | [69.8](/filings/0001493152-24-011530.md) | [93.6](/filings/0001641172-25-001720.md) | [50.9](/filings/0001641172-25-001720.md) | not reported | | Gross margin | % | [11.8%](/filings/0001493152-23-008199.md) | [16.6%](/filings/0001493152-24-011530.md) | [20.6%](/filings/0001641172-25-001720.md) | [19.5%](/filings/0001641172-25-001720.md) | not reported | | Operating margin | % | [(69.6%)](/filings/0001493152-23-008199.md) | [(20.5%)](/filings/0001493152-24-011530.md) | [0.5%](/filings/0001641172-25-001720.md) | [(6.1%)](/filings/0001493152-26-016659.md) | not reported | | Net margin | % | [(70.8%)](/filings/0001493152-23-008199.md) | [(20.2%)](/filings/0001493152-24-011530.md) | [(0.1%)](/filings/0001641172-25-001720.md) | [(66.1%)](/filings/0001493152-26-016659.md) | not reported | | Diluted EPS | $ per share | [(4.08)](/filings/0001564590-22-024599.md) | [(0.49)](/filings/0001493152-24-011530.md) | [(0.02)](/filings/0001641172-25-001720.md) | [(128.37)](/filings/0001493152-26-016659.md) | [(28.58)](/filings/0001493152-26-016659.md) | | Free cash flow | $m | [(38.5)](/filings/0001493152-23-008199.md) | [(12.4)](/filings/0001493152-24-011530.md) | [(4.1)](/filings/0001641172-25-001720.md) | [(8.7)](/filings/0001493152-26-016659.md) | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sonm/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [C2C Wealth Management, LLC](/funds/1868903.md) | 2026-06-30 | $182.8k | 35,500 | | Added +15,500 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $72.1k | 14,006 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $65.1k | 12,740 | | New +12,740 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $64.3k | 12,584 | | Reduced −2,218 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $30.2k | 5,901 | | Added +1,009 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $23.0k | 4,496 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $11.9k | 2,304 | | Reduced −33,915 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $3.3k | 642 | | Reduced −19 | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $1.1k | 214 | | Unchanged | ## Recent filings [All 520 filings](/companies/sonm/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-31 | 16:59 ET | [8-K](/filings/0001493152-26-040845.md) | 8.01 Other events | 0001493152-26-040845 | | 2026-08-27 | 07:32 ET | [8-K](/filings/0001493152-26-040324.md) | 5.02 Departure or appointment of officers or directors | 0001493152-26-040324 | | 2026-08-19 | 16:32 ET | [10-Q](/filings/0001493152-26-039226.md) | Quarterly report, period 2026-06-30 | 0001493152-26-039226 | | 2026-08-13 | 16:01 ET | [8-K/A](/filings/0001493152-26-037733.md) | 3.02 Unregistered sale of equity; 8.01 Other events | 0001493152-26-037733 | | 2026-07-09 | 16:05 ET | [8-K/A](/filings/0001493152-26-032680.md) | 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 8.01 Other events | 0001493152-26-032680 | | 2026-07-02 | 08:55 ET | [8-K](/filings/0001493152-26-031675.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001493152-26-031675 | | 2026-06-04 | 16:48 ET | [8-K](/filings/0001493152-26-027295.md) | 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001493152-26-027295 | | 2026-05-27 | 16:35 ET | [8-K](/filings/0001493152-26-025433.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.01 Delisting notice; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-26-025433 | | 2026-05-20 | 16:55 ET | [10-Q](/filings/0001493152-26-024644.md) | Quarterly report, period 2026-03-31 | 0001493152-26-024644 | | 2026-05-20 | 16:50 ET | [8-K](/filings/0001493152-26-024639.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-024639 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-016659.md), filed Apr 15, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1178697 - Tickers: SONM - Exchange: Nasdaq - SIC code: 3661 Telephone & Telegraph Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.